Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Cigna has announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk and Eli Lilly becomes a key component of ...

According to analysts, net discounts for employers on list prices range from 30% to 50%. Zepbound lists at $1,100 with a $725 net price; Wegovy lists at $1,350/month but averaged $616 net in March.

While Novo's Wegovy lists for $1,350 per month, in March the average net price for the drug was $616 according to an analysis by the Institute for Clinical and Economic Review.

The prices for Novo and Lilly’s GLP-1s are certainly much higher than those for compounded alternatives, which have generally been priced at around $200 for a month’s supply, according to Hims ...

Brian Evanko, Cigna’s president and chief operating officer, noted that the U.S. market in GLP-1 medications, used to treat diabetes and weight loss management, will reach $100 billion by 2030.